Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
349.3 USD | -0.83% | -1.94% | -23.70% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The stock, which is currently worth 2024 to 0.42 times its sales, is clearly overvalued in comparison with peers.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.70% | 42.09B | A- | ||
-3.48% | 468B | B- | ||
+10.57% | 121B | A- | ||
+11.07% | 94.49B | B- | ||
-8.08% | 19.46B | B- | ||
-27.38% | 2.57B | C+ | ||
-16.84% | 1.37B | B- | ||
+5.03% | 496M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HUM Stock
- Ratings Humana Inc.